Citadel Advisors’s The Oncology Institute Warrant TOIIW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-12,383
Closed -$87 15576
2024
Q4
$87 Sell
12,383
-5,425
-30% -$85 ﹤0.01% 14384
2024
Q3
$356 Sell
17,808
-100
-0.6% -$2 ﹤0.01% 14041
2024
Q2
$364 Buy
17,908
+4,534
+34% +$350 ﹤0.01% 14008
2024
Q1
$2.94K Sell
13,374
-8,831
-40% -$2.01K ﹤0.01% 13956
2023
Q4
$2.89K Sell
22,205
-10,624
-32% -$1.68K ﹤0.01% 13647
2023
Q3
$3.02K Buy
32,829
+4,819
+17% +$392 ﹤0.01% 13643
2023
Q2
$1.26K Buy
28,010
+10,703
+62% +$589 ﹤0.01% 13956
2023
Q1
$1.64K Buy
+17,307
New +$2.14K ﹤0.01% 14263

Other funds holding TOIIW

Citadel Advisors's TOIIW Position: Q1 2025 in Review

Citadel Advisors sold out of The Oncology Institute Warrant (TOIIW) in Q1 2025, closing a stake of 12,383 shares — an estimated $87 sold.

Citadel Advisors first reported a position in TOIIW in Q1 2023 and held it in 8 quarters. The position peaked at $3.02K in Q3 2023. 11 funds tracked by Wall St. Rank hold TOIIW as of Q1 2025.

  • Citadel Advisors reported no remaining The Oncology Institute Warrant position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 12,383 The Oncology Institute Warrant shares in Q1 2025, an estimated $87.
  • Citadel Advisors first reported a position in The Oncology Institute Warrant in Q1 2023 and held it in 8 quarters.
  • Citadel Advisors's The Oncology Institute Warrant position peaked at $3.02K in Q3 2023.
  • 11 funds tracked by Wall St. Rank held The Oncology Institute Warrant as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.